Trouble Viewing This Email: Click Here
 

July 23, 2024

Life Sciences Real Estate and Talent Trends: Insights from Matt Gardner, Head of Life Sciences, Americas, CBRE on BioTalk 

In this episode of BioTalk, Rich Bendis, President and CEO of BioHealth Innovation, Inc., speaks with Matt Gardner, Head of Life Sciences, Americas, at CBRE. With over 30 years of experience in the technology and life sciences sectors, Matt Gardner provides a comprehensive look at the latest trends and developments in the life sciences industry.

Matt shares key findings from CBRE's recently released U.S. Life Sciences Talent Trends' report for 2024, offering insights into what the life sciences sector can expect in the coming year. He discusses the national real estate market, highlighting the differences between office space and life science wet lab space, and emerging trends in the sector.

The conversation explores the strategic importance of the BioHealth Capital Region (BHCR), consistently ranked as a top market for life sciences research talent. Matt elaborates on what makes this region crucial for CBRE and the life sciences sector as a whole.

Listen now via your favorite podcast platform:
Apple: https://apple.co/4bSOnmo
Spotify: https://spoti.fi/4bVsX8r 
Amazon Music: https://amzn.to/3zLNbUw 
TuneIn: https://bit.ly/2M60Wmx

Read More

Elevate Your Startup: Apply to Compete in the 9th Annual Crab Trap Competition

Are you ready to showcase your company to some of the top minds in the industry? The 9th Annual Crab Trap competition, a highlight of the annual BioHealth Capital Region Week, is now accepting applications from emerging companies eager to demonstrate their groundbreaking solutions. Scheduled for September 18th at the US Pharmacopeia in Rockville, MD, this competition is an unmissable opportunity for startups looking to make a significant impact.

A Platform for Pioneers

The Crab Trap provides a unique platform for startups to present their innovations before a panel of esteemed judges and a live audience. This year’s competition promises exciting prizes, including cash and business services, to accelerate the winning entry’s growth and success.

Why Enter Crab Trap?

Participating in the Crab Trap competition offers numerous benefits:

  • Visibility: Gain exposure to a broad audience of industry professionals, investors, and potential partners.
  • Feedback: Receive valuable insights and feedback from leaders in the biohealth industry.
  • Prizes: Compete for a chance to win cash and services that can catalyze your company’s growth and development.

Apply Now

Read More

Forbes: Meet The New Biotech Billionaire Putting Pig Hearts In Humans

In 1996, Martine Rothblatt’s six-year-old daughter was diagnosed with pulmonary arterial hypertension, a rare lung and heart disease without a cure. Undeterred, Rothblatt, a cofounder of Sirius Satellite Radio, launched her own biotech firm with the goal of finding one.

“There is nothing worse than being told that your daughter is going to die." Forbes in 2018. “I just said I will find a way, or she was going to die, because all of the previous people with this illness had died.”

Nearly three decades later, Rothblatt’s daughter is healthy and in her 30s. Meanwhile, shares of the now publicly traded firm, United Therapeutics, are up 54 times its price at its 1999 IPO. This year alone, shares have surged, up 50% so far in 2024 and up 40% since April 30—enough to make Rothblatt the world’s newest billionaire.

Read More

Children's National Innovational District: Closing the ‘Valley of Death’: Pioneering – and paying for – new therapies

With the advent of life-changing cell and gene therapies (CGTs) to treat pediatric diseases, price is becoming a significant obstacle to care and cures.

Successful therapies can wind up shelved or in hard-to-reach clinical trials for a litany of reasons: high manufacturing costs, significant regulatory burdens, a lack of enthusiasm from the pharmaceutical industry in the small pediatric market and the simple fact that insurance companies resist paying the price of $1 million or more for a therapeutic. When successful treatments are set aside and become victims of this market failure, leaders in pediatric medicine say the drug has been relegated to the “Valley of Death.”

Experts at Children’s National Hospital and other leading U.S. research institutions are working to ferry drugs across it.

Read More

Gaithersburg's Shuttle Pharma’s new drug shows promise against estrogen receptor-positive breast cancer

Shuttle Pharma’s Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company’s HDAC inhibitor pre-clinical assets, SP-1-303, which exhibits ataxia-telangiectasia mutated protein (ATM) activation and modulation of estrogen receptor expression resulting in substantial growth inhibition of estrogen receptor positive breast cancer cells (ER + BC).

Read More

Embracing Home as a Health Care Hub: FDA's Virtual Stakeholder Listening Session

On July 25, 2024, the FDA will host a significant virtual public meeting, "Home as a Health Care Hub – Stakeholder Listening Session," from 12:00 PM to 4:00 PM ET. This session aims to explore how integrating home environments into the healthcare system can enhance health equity and patient care. The FDA seeks input from various stakeholders to identify both barriers and opportunities in this integration. Additionally, the initiative includes developing VR prototypes for managing conditions like diabetes.

Stakeholders are encouraged to register, participate, and submit comments or presentations ahead of the event.

For more information and registration details, Click here.

Read More

Discover Innovation at the 2024 NCI Technology Showcase

The National Cancer Institute's (NCI) Technology Transfer Center invites you to the 2024 Technology Showcase on September 4th, at the Frederick National Laboratory Advanced Technology Research Facility in Frederick, MD. This free, in-person event will present a remarkable lineup of cutting-edge technologies ready for commercialization. Industry experts will share their insights through engaging presentations, panel discussions on successful collaborations, and a competitive poster session highlighting innovative research.

Attendees will have the opportunity to connect with industry leaders, investors, and entrepreneurs, fostering meaningful networking and potential partnerships. The keynote speaker, Steven Walker, will deliver a compelling address on the future of biotechnology and its impact on cancer research.

The event is an exceptional platform for biotech stakeholders to discover new technologies and explore collaborative ventures. Whether you're a company, investor, or entrepreneur, the 2024 Technology Showcase offers invaluable insights and connections.

Read More

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

BioMaP-Consortium Project Agreement Will Combine Sustainable Biochemical Production with AI To Demonstrate a Scalable Platform for the Quick Manufacture of Pharmaceutical Ingredients.

STERLING, Va., July 19, 2024 (GLOBE NEWSWIRE) -- Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide more control over pharmaceutical production, boost the economy, and encourage creation of greener manufacturing methods.

Under a new $7.5 million, two-year project agreement awarded to Capra Biosciences through the BioMaP-Consortium, Capra will demonstrate the ability of its platform to rapidly scale and manufacture biologically derived small molecule active pharmaceutical ingredients (APIs). Capra has a demonstrated history of using its biofilm-forming microbes and proprietary bioreactors to transform low-cost feedstocks into a variety of chemicals, including their first commercial product, retinol.

Read More

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

WASHINGTON, July 17, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher"), a global science and technology innovator, announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs intended to accelerate the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx).

"Our investments in these centers of innovation uniquely position Danaher as a global connector across the innovation ecosystem, leveraging diagnostic technology to simplify and speed pharma translational research," said Julie Sawyer Montgomery, Executive Vice President at Danaher. "I am excited about this new way of potentially enabling our partners to more quickly bring precision treatments to market – ultimately benefiting more patients everywhere." 

Read More

FDA Rare Disease Innovation Hub to Enhance and Advance Outcomes for Patients

By: Patrizia Cavazzoni, MD, Director, Center for Drug Evaluation and Research and Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research

An estimated 10,000+ rare diseases affect more than 30 million people – approximately one out of every 10 people – in the U.S., and about half of these people are children. Many rare conditions are life threatening, and most do not have approved treatments. Fundamental to the mission of the U.S. Food and Drug Administration is to engage patients and caregivers – to understand their unique perspectives and experiences and keep these front of mind as we review medical products for rare disease patients.

The Rare Disease Innovation Hub
Recent rapid advances in the identification of promising drug targets and development of gene therapies offer momentum and potential to meet the needs of patients with rare diseases. In 2023, over half of all the novel drugs and biologics approved by the FDA’s Center for Drug Evaluation and Research (CDER) and the FDA’s Center for Biologics Evaluation and Research (CBER) were to prevent, diagnose or treat a rare disease or condition.

Read More

WBJ: D.C. maternal mental health startup Seven Starling raises $11M Series A round

D.C.-based maternal mental health startup Seven Starling has raised $10.9 million in an oversubscribed round to expand its virtual care services — which include supporting postpartum, early parenthood, infertility, miscarriage and loss and other experiences — further across the country.

San Francisco women’s health-focused venture firm RH Capital led the round and existing investors Menlo Park, California's Pear VC; San Francisco’s Expa; Santa Monica, California’s Magnify Ventures; Palo Alto, California’s Emerson Collective; and Emeryville, California’s Inflect Health also took part.

Emerson Collective is led by Laurene Powell Jobs, who is an investor in D.C.'s Monumental Sports & Entertainment, the owner of the Washington Wizards, Capitals, Mystics and other sports ventures. Emerson counts The Atlantic magazine, which is based in the District, among its holdings.

Read More

Home | About BHI | BHI News | Programs | Partners | Contact

Copyright  BioHealth Innovation 2024
All Rights Reserved.